WHO Asked To Speed Up Exploration Of Including Flu Virus Information In Benefit Sharing Scheme 07/06/2018 Catherine Saez & William New A hundred years ago, the Spanish flu infected a third of the world population, and killed more people than the two world wars combined. The World Health Organization is seeking to help the world prepare for the next pandemic, which they say, is only waiting to happen. The recent World Health Assembly agreed to ask the WHO to complete an analysis on the implications of including seasonal influenza virus and pandemic virus genetic information into its benefit-sharing mechanism to help the world face the next influenza pandemic. Separately, the UN Convention on Biological Diversity (CBD) issued a study on how to handle virus genetic information, and voiced preference for publicly accessible databases for sharing this information, rather than public domain databases, as the latter raise issue of traceability of the information from originators and also from users. And a WHO official issued a call for WHO member states to become involved in activities of the CBD's Nagoya Protocol on access and benefit-sharing to ensure health priorities are put before environmental priorities on genetic resources. Continue reading -> UNAIDS Launches New 5-Year Gender Action Plan 05/06/2018 William New UNAIDS announced today the launch of a "Gender Action Plan" for the next five years aimed at elevating women's status in the organisation worldwide. Continue reading -> Gaëlle Krikorian Named Head Of Policy At MSF Access Campaign 04/06/2018 William New The Médecins Sans Frontières’ (MSF, Doctors Without Borders) Access Campaign today announced that Gaëlle Krikorian has been named its new Head of Policy. Continue reading -> New South African Patent Policy May Impact Public Health 31/05/2018 William New The new Intellectual Property Policy of South Africa has been posted to a government website. The contains a range of measures on patenting that will affect public health. Continue reading -> 50 Years Of Global Health Progress – Interview With IFPMA Head Thomas Cueni 23/05/2018 William New Dr Tedros Adhanom Ghebreyesus, WHO Director-General in his inaugural speech at the World Health Assembly this week, explained that partnerships are a key strategy for the WHO to ensuring healthy lives and promoting well-being for all at all ages. He added that the WHO is engaging with the private sector as a crucial partner in achieving health for all. Thomas Cueni, IFPMA’s Director General, in an interview with Health Policy Watch on the occasion of the IFPMA’s 50-year anniversary, explains how the research-based biopharmaceutical industry together with IFPMA have contributed to the huge strides in health progress over 50 years. He explains the major leaps forward, setbacks and mistakes, as well as how industry is part of the solution, as "do-ers" and partners in global health progress. Cueni also talks about pricing and cost of R&D. Continue reading -> WHO Issues First-Ever List Of Essential Diagnostic Tests 15/05/2018 William New The World Health Organization today published its first Essential Diagnostics List, which identifies the most-needed tests for conditions and diseases. Continue reading -> Trump Declares Intent To Stop Pharma Companies From ‘Gaming’ Patent System 11/05/2018 William New US President Trump today declared in a White House speech his intent to "take steps" to lower drug prices by stopping "gaming of regulatory and patent processes by drug makers to unfairly protect monopolies," as well as increasing price transparency and promoting biosimilars and generics. But to do this, his administration will take on what it sees as "freeloading" on US innovation by foreign governments, and addressing "unfair" intellectual property and market access policies in trade agreements. Continue reading -> Evergreened Patents Cause Unwarranted High Drug Prices, Hinder Growth Of Local Producers – NGOs, Thai Producers Claim 07/05/2018 William New BANGKOK - Transnational drug manufacturers’ tactics of obtaining unmerited patent applications have unnecessarily raised healthcare costs and impeded the growth of domestic generic drug industry, costing the Thai government hundreds of millions of dollars, drug access campaigners and local producers have said. Continue reading -> USTR IP Report Sparks Outcry Among Health Advocates 27/04/2018 William New The annual Special 301 report of the Office of the United States Trade Representative (USTR) issued today sparked a quick outcry among health advocates over its seemingly more restrictive approach they say bullies other countries into unfairly promoting US pharmaceutical industry rights to an extent that would raise drug prices and limit accessibility. Continue reading -> USTR Annual Special 301 Report Intensifies Action On China, Colombia, Canada 27/04/2018 William New The annual report of the Office of the United States Trade Representative (USTR) on the adequacy of trading partners’ protection of US intellectual property rights celebrated its 30th year this year with a sharper tone with China, in keeping with the Trump administration’s tough stance on the country. Also caught in the report are Colombia and Canada, which were downgraded to the “priority watch list.” Also, this year the report includes a special highlight on pharmaceuticals and medical devices. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
UNAIDS Launches New 5-Year Gender Action Plan 05/06/2018 William New UNAIDS announced today the launch of a "Gender Action Plan" for the next five years aimed at elevating women's status in the organisation worldwide. Continue reading -> Gaëlle Krikorian Named Head Of Policy At MSF Access Campaign 04/06/2018 William New The Médecins Sans Frontières’ (MSF, Doctors Without Borders) Access Campaign today announced that Gaëlle Krikorian has been named its new Head of Policy. Continue reading -> New South African Patent Policy May Impact Public Health 31/05/2018 William New The new Intellectual Property Policy of South Africa has been posted to a government website. The contains a range of measures on patenting that will affect public health. Continue reading -> 50 Years Of Global Health Progress – Interview With IFPMA Head Thomas Cueni 23/05/2018 William New Dr Tedros Adhanom Ghebreyesus, WHO Director-General in his inaugural speech at the World Health Assembly this week, explained that partnerships are a key strategy for the WHO to ensuring healthy lives and promoting well-being for all at all ages. He added that the WHO is engaging with the private sector as a crucial partner in achieving health for all. Thomas Cueni, IFPMA’s Director General, in an interview with Health Policy Watch on the occasion of the IFPMA’s 50-year anniversary, explains how the research-based biopharmaceutical industry together with IFPMA have contributed to the huge strides in health progress over 50 years. He explains the major leaps forward, setbacks and mistakes, as well as how industry is part of the solution, as "do-ers" and partners in global health progress. Cueni also talks about pricing and cost of R&D. Continue reading -> WHO Issues First-Ever List Of Essential Diagnostic Tests 15/05/2018 William New The World Health Organization today published its first Essential Diagnostics List, which identifies the most-needed tests for conditions and diseases. Continue reading -> Trump Declares Intent To Stop Pharma Companies From ‘Gaming’ Patent System 11/05/2018 William New US President Trump today declared in a White House speech his intent to "take steps" to lower drug prices by stopping "gaming of regulatory and patent processes by drug makers to unfairly protect monopolies," as well as increasing price transparency and promoting biosimilars and generics. But to do this, his administration will take on what it sees as "freeloading" on US innovation by foreign governments, and addressing "unfair" intellectual property and market access policies in trade agreements. Continue reading -> Evergreened Patents Cause Unwarranted High Drug Prices, Hinder Growth Of Local Producers – NGOs, Thai Producers Claim 07/05/2018 William New BANGKOK - Transnational drug manufacturers’ tactics of obtaining unmerited patent applications have unnecessarily raised healthcare costs and impeded the growth of domestic generic drug industry, costing the Thai government hundreds of millions of dollars, drug access campaigners and local producers have said. Continue reading -> USTR IP Report Sparks Outcry Among Health Advocates 27/04/2018 William New The annual Special 301 report of the Office of the United States Trade Representative (USTR) issued today sparked a quick outcry among health advocates over its seemingly more restrictive approach they say bullies other countries into unfairly promoting US pharmaceutical industry rights to an extent that would raise drug prices and limit accessibility. Continue reading -> USTR Annual Special 301 Report Intensifies Action On China, Colombia, Canada 27/04/2018 William New The annual report of the Office of the United States Trade Representative (USTR) on the adequacy of trading partners’ protection of US intellectual property rights celebrated its 30th year this year with a sharper tone with China, in keeping with the Trump administration’s tough stance on the country. Also caught in the report are Colombia and Canada, which were downgraded to the “priority watch list.” Also, this year the report includes a special highlight on pharmaceuticals and medical devices. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Gaëlle Krikorian Named Head Of Policy At MSF Access Campaign 04/06/2018 William New The Médecins Sans Frontières’ (MSF, Doctors Without Borders) Access Campaign today announced that Gaëlle Krikorian has been named its new Head of Policy. Continue reading -> New South African Patent Policy May Impact Public Health 31/05/2018 William New The new Intellectual Property Policy of South Africa has been posted to a government website. The contains a range of measures on patenting that will affect public health. Continue reading -> 50 Years Of Global Health Progress – Interview With IFPMA Head Thomas Cueni 23/05/2018 William New Dr Tedros Adhanom Ghebreyesus, WHO Director-General in his inaugural speech at the World Health Assembly this week, explained that partnerships are a key strategy for the WHO to ensuring healthy lives and promoting well-being for all at all ages. He added that the WHO is engaging with the private sector as a crucial partner in achieving health for all. Thomas Cueni, IFPMA’s Director General, in an interview with Health Policy Watch on the occasion of the IFPMA’s 50-year anniversary, explains how the research-based biopharmaceutical industry together with IFPMA have contributed to the huge strides in health progress over 50 years. He explains the major leaps forward, setbacks and mistakes, as well as how industry is part of the solution, as "do-ers" and partners in global health progress. Cueni also talks about pricing and cost of R&D. Continue reading -> WHO Issues First-Ever List Of Essential Diagnostic Tests 15/05/2018 William New The World Health Organization today published its first Essential Diagnostics List, which identifies the most-needed tests for conditions and diseases. Continue reading -> Trump Declares Intent To Stop Pharma Companies From ‘Gaming’ Patent System 11/05/2018 William New US President Trump today declared in a White House speech his intent to "take steps" to lower drug prices by stopping "gaming of regulatory and patent processes by drug makers to unfairly protect monopolies," as well as increasing price transparency and promoting biosimilars and generics. But to do this, his administration will take on what it sees as "freeloading" on US innovation by foreign governments, and addressing "unfair" intellectual property and market access policies in trade agreements. Continue reading -> Evergreened Patents Cause Unwarranted High Drug Prices, Hinder Growth Of Local Producers – NGOs, Thai Producers Claim 07/05/2018 William New BANGKOK - Transnational drug manufacturers’ tactics of obtaining unmerited patent applications have unnecessarily raised healthcare costs and impeded the growth of domestic generic drug industry, costing the Thai government hundreds of millions of dollars, drug access campaigners and local producers have said. Continue reading -> USTR IP Report Sparks Outcry Among Health Advocates 27/04/2018 William New The annual Special 301 report of the Office of the United States Trade Representative (USTR) issued today sparked a quick outcry among health advocates over its seemingly more restrictive approach they say bullies other countries into unfairly promoting US pharmaceutical industry rights to an extent that would raise drug prices and limit accessibility. Continue reading -> USTR Annual Special 301 Report Intensifies Action On China, Colombia, Canada 27/04/2018 William New The annual report of the Office of the United States Trade Representative (USTR) on the adequacy of trading partners’ protection of US intellectual property rights celebrated its 30th year this year with a sharper tone with China, in keeping with the Trump administration’s tough stance on the country. Also caught in the report are Colombia and Canada, which were downgraded to the “priority watch list.” Also, this year the report includes a special highlight on pharmaceuticals and medical devices. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
New South African Patent Policy May Impact Public Health 31/05/2018 William New The new Intellectual Property Policy of South Africa has been posted to a government website. The contains a range of measures on patenting that will affect public health. Continue reading -> 50 Years Of Global Health Progress – Interview With IFPMA Head Thomas Cueni 23/05/2018 William New Dr Tedros Adhanom Ghebreyesus, WHO Director-General in his inaugural speech at the World Health Assembly this week, explained that partnerships are a key strategy for the WHO to ensuring healthy lives and promoting well-being for all at all ages. He added that the WHO is engaging with the private sector as a crucial partner in achieving health for all. Thomas Cueni, IFPMA’s Director General, in an interview with Health Policy Watch on the occasion of the IFPMA’s 50-year anniversary, explains how the research-based biopharmaceutical industry together with IFPMA have contributed to the huge strides in health progress over 50 years. He explains the major leaps forward, setbacks and mistakes, as well as how industry is part of the solution, as "do-ers" and partners in global health progress. Cueni also talks about pricing and cost of R&D. Continue reading -> WHO Issues First-Ever List Of Essential Diagnostic Tests 15/05/2018 William New The World Health Organization today published its first Essential Diagnostics List, which identifies the most-needed tests for conditions and diseases. Continue reading -> Trump Declares Intent To Stop Pharma Companies From ‘Gaming’ Patent System 11/05/2018 William New US President Trump today declared in a White House speech his intent to "take steps" to lower drug prices by stopping "gaming of regulatory and patent processes by drug makers to unfairly protect monopolies," as well as increasing price transparency and promoting biosimilars and generics. But to do this, his administration will take on what it sees as "freeloading" on US innovation by foreign governments, and addressing "unfair" intellectual property and market access policies in trade agreements. Continue reading -> Evergreened Patents Cause Unwarranted High Drug Prices, Hinder Growth Of Local Producers – NGOs, Thai Producers Claim 07/05/2018 William New BANGKOK - Transnational drug manufacturers’ tactics of obtaining unmerited patent applications have unnecessarily raised healthcare costs and impeded the growth of domestic generic drug industry, costing the Thai government hundreds of millions of dollars, drug access campaigners and local producers have said. Continue reading -> USTR IP Report Sparks Outcry Among Health Advocates 27/04/2018 William New The annual Special 301 report of the Office of the United States Trade Representative (USTR) issued today sparked a quick outcry among health advocates over its seemingly more restrictive approach they say bullies other countries into unfairly promoting US pharmaceutical industry rights to an extent that would raise drug prices and limit accessibility. Continue reading -> USTR Annual Special 301 Report Intensifies Action On China, Colombia, Canada 27/04/2018 William New The annual report of the Office of the United States Trade Representative (USTR) on the adequacy of trading partners’ protection of US intellectual property rights celebrated its 30th year this year with a sharper tone with China, in keeping with the Trump administration’s tough stance on the country. Also caught in the report are Colombia and Canada, which were downgraded to the “priority watch list.” Also, this year the report includes a special highlight on pharmaceuticals and medical devices. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
50 Years Of Global Health Progress – Interview With IFPMA Head Thomas Cueni 23/05/2018 William New Dr Tedros Adhanom Ghebreyesus, WHO Director-General in his inaugural speech at the World Health Assembly this week, explained that partnerships are a key strategy for the WHO to ensuring healthy lives and promoting well-being for all at all ages. He added that the WHO is engaging with the private sector as a crucial partner in achieving health for all. Thomas Cueni, IFPMA’s Director General, in an interview with Health Policy Watch on the occasion of the IFPMA’s 50-year anniversary, explains how the research-based biopharmaceutical industry together with IFPMA have contributed to the huge strides in health progress over 50 years. He explains the major leaps forward, setbacks and mistakes, as well as how industry is part of the solution, as "do-ers" and partners in global health progress. Cueni also talks about pricing and cost of R&D. Continue reading -> WHO Issues First-Ever List Of Essential Diagnostic Tests 15/05/2018 William New The World Health Organization today published its first Essential Diagnostics List, which identifies the most-needed tests for conditions and diseases. Continue reading -> Trump Declares Intent To Stop Pharma Companies From ‘Gaming’ Patent System 11/05/2018 William New US President Trump today declared in a White House speech his intent to "take steps" to lower drug prices by stopping "gaming of regulatory and patent processes by drug makers to unfairly protect monopolies," as well as increasing price transparency and promoting biosimilars and generics. But to do this, his administration will take on what it sees as "freeloading" on US innovation by foreign governments, and addressing "unfair" intellectual property and market access policies in trade agreements. Continue reading -> Evergreened Patents Cause Unwarranted High Drug Prices, Hinder Growth Of Local Producers – NGOs, Thai Producers Claim 07/05/2018 William New BANGKOK - Transnational drug manufacturers’ tactics of obtaining unmerited patent applications have unnecessarily raised healthcare costs and impeded the growth of domestic generic drug industry, costing the Thai government hundreds of millions of dollars, drug access campaigners and local producers have said. Continue reading -> USTR IP Report Sparks Outcry Among Health Advocates 27/04/2018 William New The annual Special 301 report of the Office of the United States Trade Representative (USTR) issued today sparked a quick outcry among health advocates over its seemingly more restrictive approach they say bullies other countries into unfairly promoting US pharmaceutical industry rights to an extent that would raise drug prices and limit accessibility. Continue reading -> USTR Annual Special 301 Report Intensifies Action On China, Colombia, Canada 27/04/2018 William New The annual report of the Office of the United States Trade Representative (USTR) on the adequacy of trading partners’ protection of US intellectual property rights celebrated its 30th year this year with a sharper tone with China, in keeping with the Trump administration’s tough stance on the country. Also caught in the report are Colombia and Canada, which were downgraded to the “priority watch list.” Also, this year the report includes a special highlight on pharmaceuticals and medical devices. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
WHO Issues First-Ever List Of Essential Diagnostic Tests 15/05/2018 William New The World Health Organization today published its first Essential Diagnostics List, which identifies the most-needed tests for conditions and diseases. Continue reading -> Trump Declares Intent To Stop Pharma Companies From ‘Gaming’ Patent System 11/05/2018 William New US President Trump today declared in a White House speech his intent to "take steps" to lower drug prices by stopping "gaming of regulatory and patent processes by drug makers to unfairly protect monopolies," as well as increasing price transparency and promoting biosimilars and generics. But to do this, his administration will take on what it sees as "freeloading" on US innovation by foreign governments, and addressing "unfair" intellectual property and market access policies in trade agreements. Continue reading -> Evergreened Patents Cause Unwarranted High Drug Prices, Hinder Growth Of Local Producers – NGOs, Thai Producers Claim 07/05/2018 William New BANGKOK - Transnational drug manufacturers’ tactics of obtaining unmerited patent applications have unnecessarily raised healthcare costs and impeded the growth of domestic generic drug industry, costing the Thai government hundreds of millions of dollars, drug access campaigners and local producers have said. Continue reading -> USTR IP Report Sparks Outcry Among Health Advocates 27/04/2018 William New The annual Special 301 report of the Office of the United States Trade Representative (USTR) issued today sparked a quick outcry among health advocates over its seemingly more restrictive approach they say bullies other countries into unfairly promoting US pharmaceutical industry rights to an extent that would raise drug prices and limit accessibility. Continue reading -> USTR Annual Special 301 Report Intensifies Action On China, Colombia, Canada 27/04/2018 William New The annual report of the Office of the United States Trade Representative (USTR) on the adequacy of trading partners’ protection of US intellectual property rights celebrated its 30th year this year with a sharper tone with China, in keeping with the Trump administration’s tough stance on the country. Also caught in the report are Colombia and Canada, which were downgraded to the “priority watch list.” Also, this year the report includes a special highlight on pharmaceuticals and medical devices. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Trump Declares Intent To Stop Pharma Companies From ‘Gaming’ Patent System 11/05/2018 William New US President Trump today declared in a White House speech his intent to "take steps" to lower drug prices by stopping "gaming of regulatory and patent processes by drug makers to unfairly protect monopolies," as well as increasing price transparency and promoting biosimilars and generics. But to do this, his administration will take on what it sees as "freeloading" on US innovation by foreign governments, and addressing "unfair" intellectual property and market access policies in trade agreements. Continue reading -> Evergreened Patents Cause Unwarranted High Drug Prices, Hinder Growth Of Local Producers – NGOs, Thai Producers Claim 07/05/2018 William New BANGKOK - Transnational drug manufacturers’ tactics of obtaining unmerited patent applications have unnecessarily raised healthcare costs and impeded the growth of domestic generic drug industry, costing the Thai government hundreds of millions of dollars, drug access campaigners and local producers have said. Continue reading -> USTR IP Report Sparks Outcry Among Health Advocates 27/04/2018 William New The annual Special 301 report of the Office of the United States Trade Representative (USTR) issued today sparked a quick outcry among health advocates over its seemingly more restrictive approach they say bullies other countries into unfairly promoting US pharmaceutical industry rights to an extent that would raise drug prices and limit accessibility. Continue reading -> USTR Annual Special 301 Report Intensifies Action On China, Colombia, Canada 27/04/2018 William New The annual report of the Office of the United States Trade Representative (USTR) on the adequacy of trading partners’ protection of US intellectual property rights celebrated its 30th year this year with a sharper tone with China, in keeping with the Trump administration’s tough stance on the country. Also caught in the report are Colombia and Canada, which were downgraded to the “priority watch list.” Also, this year the report includes a special highlight on pharmaceuticals and medical devices. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Evergreened Patents Cause Unwarranted High Drug Prices, Hinder Growth Of Local Producers – NGOs, Thai Producers Claim 07/05/2018 William New BANGKOK - Transnational drug manufacturers’ tactics of obtaining unmerited patent applications have unnecessarily raised healthcare costs and impeded the growth of domestic generic drug industry, costing the Thai government hundreds of millions of dollars, drug access campaigners and local producers have said. Continue reading -> USTR IP Report Sparks Outcry Among Health Advocates 27/04/2018 William New The annual Special 301 report of the Office of the United States Trade Representative (USTR) issued today sparked a quick outcry among health advocates over its seemingly more restrictive approach they say bullies other countries into unfairly promoting US pharmaceutical industry rights to an extent that would raise drug prices and limit accessibility. Continue reading -> USTR Annual Special 301 Report Intensifies Action On China, Colombia, Canada 27/04/2018 William New The annual report of the Office of the United States Trade Representative (USTR) on the adequacy of trading partners’ protection of US intellectual property rights celebrated its 30th year this year with a sharper tone with China, in keeping with the Trump administration’s tough stance on the country. Also caught in the report are Colombia and Canada, which were downgraded to the “priority watch list.” Also, this year the report includes a special highlight on pharmaceuticals and medical devices. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
USTR IP Report Sparks Outcry Among Health Advocates 27/04/2018 William New The annual Special 301 report of the Office of the United States Trade Representative (USTR) issued today sparked a quick outcry among health advocates over its seemingly more restrictive approach they say bullies other countries into unfairly promoting US pharmaceutical industry rights to an extent that would raise drug prices and limit accessibility. Continue reading -> USTR Annual Special 301 Report Intensifies Action On China, Colombia, Canada 27/04/2018 William New The annual report of the Office of the United States Trade Representative (USTR) on the adequacy of trading partners’ protection of US intellectual property rights celebrated its 30th year this year with a sharper tone with China, in keeping with the Trump administration’s tough stance on the country. Also caught in the report are Colombia and Canada, which were downgraded to the “priority watch list.” Also, this year the report includes a special highlight on pharmaceuticals and medical devices. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
USTR Annual Special 301 Report Intensifies Action On China, Colombia, Canada 27/04/2018 William New The annual report of the Office of the United States Trade Representative (USTR) on the adequacy of trading partners’ protection of US intellectual property rights celebrated its 30th year this year with a sharper tone with China, in keeping with the Trump administration’s tough stance on the country. Also caught in the report are Colombia and Canada, which were downgraded to the “priority watch list.” Also, this year the report includes a special highlight on pharmaceuticals and medical devices. Continue reading -> Posts navigation Older postsNewer posts